What question did this study set out to answer?

The aim is to evaluate the clinical performance of the Optim.AI™ platform in predicting treatment responses for hematological malignancies.

Clinical Performance of Optim.AI™ in Hematological Malignancies

View Full Paper

Ask AI

Bookmark

The aim is to evaluate the clinical performance of the Optim.AI™ platform in predicting treatment responses for hematological malignancies.
Isolated tumor cells from solid tissues, peripheral blood, or bone marrow aspirates.
Exposed cells to 12 FDA-approved chemotherapy and targeted agents in combinatorial formats.
Quantified post-treatment cell viability to generate Optim.AI™ rankings of treatment combinations.
Conducted retrospective assessment of clinical outcomes for patients guided by Optim.AI™ therapies.
91% of 154 hematological samples yielded sufficient cells for testing, with 94% producing successful reports.
88% of cases showed predicted normalized cell viability (NCV) > 0.6, correlating with clinical resistance.
In acute myeloid leukemia patients, the platform was clinically useful in all cases, resulting in two complete remissions.
Two non-responders had NCV > 0.6, accurately predicting non-response and facilitating transitions to palliative care.

No takes yet. Share an insight, caveat, or question.

Real-world analysis demonstrates that Optim.AI™ predicts treatment responses in hematological malignancies, suggesting its clinical utility.

Rashid et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Real-world analysis demonstrates that Optim.AI™ predicts treatment responses in hematological malignancies, suggesting its clinical utility.